Company
IsraelPublic company, NYSE: PLXProtalix Biotherapeutics (NYSE: PLX), Karmiel, Israel – FDA Inspections
Inspection records and compliance data for Protalix Biotherapeutics in Karmiel. 1 FDA inspection on record, last inspected November 11, 2010. Publicly traded as NYSE: PLX.
Company Profile
This profile covers Protalix Biotherapeutics based in Karmiel, Israel.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected November 11, 2010.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| November 11, 2010 | NAI | Human Drugs · Bioresearch Monitoring | 700465 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Protalix Biotherapeutics
Stock ticker
PLX
Exchange
NYSE
Share price
$2.96
Market cap
$249.2M
Price as of
November 13, 2026
FEI Number
3006476365
Address
Science Park, 2, Snunit St, Karmiel, Israel
Country
Israel
ID: 7c95faf3-0d7f-4c96-8fb3-ed4b7c4c5fdd